Apr062016

Waldenstrom’s Macroglobulinemia Patient & Caregiver Surveys

Waldenstrom’s Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Patient & Caregiver Surveys

If you have Waldenstrom’s Macroglobulinemia (WM) or you are a caregiver of a patient with WM, you can help by completing our surveys.

Lymphoma Canada, in partnership with the Canadian Organization for Rare Disorders (CORD), is preparing a submission to the pan­Canadian Oncology Drug Review (pCODR) for:

Ibrutinib (Imbruvica) for patients with Waldenstrom’s Macroglobulinemia (WM) who have received at least one prior therapy

The surveys provide us with the patient and caregiver input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete a survey.

BY COMPLETING A SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The surveys will be open until midnight Pacific Time on Wednesday, April 27th and should only take 10 minutes of your time.

You may access the survey by clicking the appropriate link below.

Survey for WM Patients with Ibrutinib (Imbruvica) Experience

Survey for WM Patients who have NOT been treated with Ibrutinib (Imbruvica)

Survey for Caregivers

Please share and help us spread the word.

Thank you for your support.

Like with Social Media